Alembic Pharmaceuticals Limited (NSE: APLLTD)
India
· Delayed Price · Currency is INR 1,217.95
-24.90 (-2.00%)
Oct 7, 2024, 3:30 PM IST
Alembic Pharmaceuticals Revenue
Alembic Pharmaceuticals had revenue of 15.62B INR in the quarter ending June 30, 2024, with 5.09% growth. This brings the company's revenue in the last twelve months to 63.04B, up 7.28% year-over-year. In the fiscal year ending March 31, 2024, Alembic Pharmaceuticals had annual revenue of 62.29B with 10.19% growth.
Revenue (ttm)
63.04B
Revenue Growth
+7.28%
P/S Ratio
3.72
Revenue / Employee
4.24M
Employees
14,858
Market Cap
234.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 62.29B | 5.76B | 10.19% |
| Mar 31, 2023 | 56.53B | 3.47B | 6.54% |
| Mar 31, 2022 | 53.06B | -873.40M | -1.62% |
| Mar 31, 2021 | 53.93B | 7.87B | 17.10% |
| Mar 31, 2020 | 46.06B | 6.71B | 17.06% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAlembic Pharmaceuticals News
- 13 days ago - Alembic Pharmaceuticals receives USFDA final approval for Paliperidone Extended-Release Tablets - Business Upturn
- 4 weeks ago - Alembic Pharmaceuticals stock surges 4% after getting USFDA approval for Albendazole tablets - Business Upturn
- 5 weeks ago - Alembic Pharmaceuticals share jumps 3% after getting USFDA approval for Albendazole tablets - Business Upturn
- 5 weeks ago - Alembic Pharmaceuticals gets USFDA nod for Albendazole tablets - Business Upturn
- 6 weeks ago - USFDA greenlights Alembic Pharmaceutical’s Betamethasone Valerate Foam - Business Upturn